Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy receives final approval for simvastatin in Canada

This article was originally published in Scrip

Executive Summary

Ranbaxy Laboratories has received final approval from Health Canada's Therapeutic Products Directorate to manufacture and market the lipid metabolism regulator, Ran-Simvastatin 5mg, 10mg, 20mg, 40mg and 80mg tablets (simvastatin), there. The company expects to launch Ran-Simvastatin in September at an affordable price that would benefit the Canadian healthcare system and patients. The generic market for simvastatin tablets in Canada is estimated at Cdn$153 million ($138.2 million).






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts